A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Atara Biotherapeutics
- 04 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 04 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 27 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History